Biogen investigates a death possibly linked to its controversial new Alzheimer's drug
Biogen is investigating the death of a 75-year-old patient potentially linked to the company’s new Alzheimer’s drug, which the FDA controversially approved via its accelerated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
